Bortezomib Reinduction Chemotherapy in High-Risk ALL in First Relapse: A Report from the Children’s Oncology Group

While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children’s Oncology Group study tested the hypothesis that adding the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O’Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606340/
https://ncbi.nlm.nih.gov/pubmed/30957229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15919
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi